POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
28 hedge funds and large institutions have $149M invested in POINT Biopharma Global Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
12% more funds holding
Funds holding: 25 → 28 (+3)
19% less capital invested
Capital invested by funds: $184M → $149M (-$35.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$14.6M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$9.49M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.09M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.51M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.19M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.48M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$687K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$658K |
PNT Hedge Fund Activity: Q1 2021 in Review
28 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q1 2021, worth a combined $149M — down 19% from $184M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PNT positions and 6 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $14.6M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $12.9M sold.
- 28 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q1 2021, up from 25 in Q4 2020.
- Funds reported $149M of POINT Biopharma Global Inc. Common Stock stock for Q1 2021, down 19% quarter-over-quarter.
- 9 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q1 2021 and 6 closed out, a net change of +3 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q1 2021 was Suvretta Capital Management, an estimated $14.6M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q1 2021 was T. Rowe Price Associates, an estimated $12.9M sold.
Based on aggregated 13F filings for Q1 2021.